These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086 [TBL] [Abstract][Full Text] [Related]
4. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133 [TBL] [Abstract][Full Text] [Related]
5. Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739 [TBL] [Abstract][Full Text] [Related]
6. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342 [TBL] [Abstract][Full Text] [Related]
7. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. Iñarrairaegui M; Martinez-Cuesta A; Rodríguez M; Bilbao JI; Arbizu J; Benito A; Alegre F; D'Avola D; Herrero JI; Quiroga J; Prieto J; Sangro B Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1441-8. PubMed ID: 20056355 [TBL] [Abstract][Full Text] [Related]
8. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases. Kousik V; Promila P; Verma R; Gupta A Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180 [TBL] [Abstract][Full Text] [Related]
9. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET. Sabet A; Ahmadzadehfar H; Bruhman J; Sabet A; Meyer C; Wasmuth JC; Pieper CC; Biersack HJ; Ezziddin S Nuklearmedizin; 2014; 53(2):39-45. PubMed ID: 24777354 [TBL] [Abstract][Full Text] [Related]
11. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. Kokabi N; Camacho JC; Xing M; Qiu D; Kitajima H; Mittal PK; Kim HS Abdom Imaging; 2014 Oct; 39(5):969-78. PubMed ID: 24740759 [TBL] [Abstract][Full Text] [Related]
12. Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion. Reiner CS; Morsbach F; Sah BR; Puippe G; Schaefer N; Pfammatter T; Alkadhi H J Vasc Interv Radiol; 2014 May; 25(5):747-59. PubMed ID: 24630751 [TBL] [Abstract][Full Text] [Related]
13. Metabolic activity assessment by Kim DY; Lee HW; Kang W; Kim GM; Won JY; Yun M J Gastroenterol Hepatol; 2021 Jun; 36(6):1679-1684. PubMed ID: 33226706 [TBL] [Abstract][Full Text] [Related]
14. Utility of Early Posttreatment PET/CT Evaluation Using FDG or Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448 [No Abstract] [Full Text] [Related]
15. The MAAPE score in intermediate and advanced hepatocellular carcinoma treated with Yttrium-90 resin microsphere radioembolization. Wallace MC; Samuelson S; Khoo T; Ooi J; Tibballs J; Ferguson J; Preen DB; Knuiman M; Garas G; MacQuillan G; Adams LA; Jeffrey GP J Gastroenterol Hepatol; 2020 Nov; 35(11):1945-1952. PubMed ID: 32036614 [TBL] [Abstract][Full Text] [Related]
16. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745 [TBL] [Abstract][Full Text] [Related]
17. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients. Saxena A; Meteling B; Kapoor J; Golani S; Danta M; Morris DL; Bester L Int J Surg; 2014 Dec; 12(12):1403-8. PubMed ID: 25091398 [TBL] [Abstract][Full Text] [Related]
18. Prediction of hepatocellular carcinoma response to Gordic S; Wagner M; Zanato R; Hectors S; Besa C; Kihira S; Kim E; Taouli B Cancer Imaging; 2019 May; 19(1):29. PubMed ID: 31142363 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S; J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371 [TBL] [Abstract][Full Text] [Related]
20. Imaging of Hepatocellular Carcinoma Response After Semaan S; Makkar J; Lewis S; Chatterji M; Kim E; Taouli B AJR Am J Roentgenol; 2017 Nov; 209(5):W263-W276. PubMed ID: 29072955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]